Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis

被引：4

作者：

Mastrantoni, Luca ^{[1
,3
]}

Beccia, Viria ^{[1
]}

Caira, Giulia ^{[1
]}

Trovato, Giovanni ^{[1
]}

Calegari, Maria Alessandra ^{[2
]}

Basso, Michele ^{[2
]}

Salvatore, Lisa ^{[1
,2
]}

Pozzo, Carmelo ^{[2
]}

Tortora, Giampaolo ^{[1
,2
]}

Bria, Emilio ^{[1
,2
]}

Orlandi, Armando ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Med Oncol, Rome, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Comprehens Canc Ctr, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Med Oncol Dept, Via Pineta Sacchetti 217, I-00168 Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 191卷

关键词：

Maintenance therapy; Anti-EGFR; Cetuximab; Panitumumab; Meta-analysis; FOLFIRI PLUS BEVACIZUMAB; EARLY TUMOR SHRINKAGE; 1ST-LINE TREATMENT; OPEN-LABEL; RAS; CETUXIMAB; CHEMOTHERAPY; INTERMITTENT; MULTICENTER; PANITUMUMAB;

D O I：

10.1016/j.critrevonc.2023.104106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In RAS wild type (wt) metastatic colorectal cancer (mCRC) maintenance therapy after induction with fluoropyrimidine (FP)-based cytotoxic therapy (CT) plus anti-EGFR agents is controversial.Methods: Phase II-III randomized trials were included. Maintenance strategies considered were: observation, antiEGFR or FP monotherapy, FP + anti-EGFR, doublet CT + anti-EGFR.Results: Maintenance with FP + anti-EGFR (HR 0.56, 95% CrI 0.36-0.89) showed the greatest PFS benefit compared to observation, ranking first on SUCRA analysis (96.4%). Considering OS, doublet CT+ anti-EGFR, FP + anti-EGFR and anti-EGFR monotherapy yielded similar results. For PFS, FP + anti-EGFR confirmed to be valuable in BRAF wt patients and left sided tumors. In left sided tumors, the OS benefit of adding CT was limited. FP plus anti-EGFR showed a favourable safety profile compared to doublet CT + anti-EGFR. Conclusions: FP + anti-EGFR can be considered a valuable maintenance option in RAS wt mCRC. EGFR monotherapy can be considered, especially in left-sided tumors.

引用

页数：8

共 35 条

[31] Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study [J].

Vayrynen, V. ;

Wirta, E. -V. ;

Seppala, T. ;

Sihvo, E. ;

Mecklin, J. -P. ;

Vasala, K. ;

Kellokumpu, I. .

BJS OPEN, 2020, 4 (04) :685-692

[32] Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years [J].

Vuik, Fanny E. R. ;

Nieuwenburg, Stella A. V. ;

Bardou, Marc ;

Lansdorp-Vogelaar, Iris ;

Dinis-Ribeiro, Mario ;

Bento, Maria J. ;

Zadnik, Vesna ;

Pellise, Maria ;

Esteban, Laura ;

Kaminski, Michal F. ;

Suchanek, Stepan ;

Ngo, Ondrej ;

Majek, Ondrej ;

Leja, Marcis ;

Kuipers, Ernst J. ;

Spaander, Manon C. W. .

GUT, 2019, 68 (10) :1820-1826

[33] Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer A Phase 2 Clinical Trial [J].

Wang, Lu ;

Liu, Ying ;

Yin, Xianli ;

Fang, Weijia ;

Xiong, Jianping ;

Zhao, Ben ;

Zhang, Mingsheng ;

Zou, Yanmei ;

Qiu, Hong ;

Yuan, Xianglin .

JAMA NETWORK OPEN, 2020, 3 (07)

[34] Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial [J].

Wasan, Harpreet ;

Meade, Angela M. ;

Adams, Richard ;

Wilson, Richard ;

Pugh, Cheryl ;

Fisher, David ;

Sydes, Benjamin ;

Madi, Ayman ;

Sizer, Bruce ;

Lowdell, Charles ;

Middleton, Gary ;

Butler, Rachel ;

Kaplan, Richard ;

Maughan, Tim .

LANCET ONCOLOGY, 2014, 15 (06) :631-639

[35]

Yoshino T, 2022, J CLIN ONCOL, V40

← 1 2 3 4 →